ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMGastos comerciales, generales y administrativos792.2 M633 M634.2 M657.8 M775 M647.7 M2.71 BInvestigación y desarrollo1.41 B1.33 B1.42 B1.48 B1.63 B1.54 B6.07 BBeneficio operativo990.2 M591.7 M1.08 B1.03 B879.9 M642.9 M3.63 BTotal de ingresos no operativos-32.1 M313.3 M439.2 M736.5 M163.8 M188.3 M1.53 BGastos por intereses, netos de intereses capitalizados10.5 M8.7 M3.6 M19.3 M12.2 M12.9 M48 MIngresos no operativos, una vez deducidos los gastos por intereses-10.5 M-8.7 M-7.2 M-38.6 M-24.4 M-25.8 M-96 MIngresos/gastos extraordinarios-21.6 M322 M442.8 M755.8 M176 M201.2 M1.58 BBeneficio antes de impuestos958.1 M905 M1.52 B1.76 B1.04 B831.2 M5.16 BParticipación en los beneficios———————Impuestos40.4 M96.3 M127.1 M303.3 M199.1 M104 M733.5 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos-55.4 M-3.2 M20.9 M-16.3 M-136.9 M-55.6 M-187.9 MBeneficio neto antes de actividades interrumpidas917.7 M808.7 M1.39 B1.46 B844.6 M727.2 M4.42 BOperaciones suspendidas———————Beneficio neto917.7 M808.7 M1.39 B1.46 B844.6 M727.2 M4.42 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas917.7 M808.7 M1.39 B1.46 B844.6 M727.2 M4.42 BBeneficio básico por acción8.557.5813.2414.098.166.9942.48Beneficio por acción diluido8.127.2712.8113.627.786.7540.96Número medio de acciones ordinarias107.9 M106.7 M105.1 M103.6 M104.6 M104 M—Acciones diluidas115.1 M111.2 M108.6 M107.2 M108.6 M107.7 M—EBITDA1.12 B718.6 M1.21 B1.16 B1.02 B766.1 M4.17 BEBIT990.2 M591.7 M1.08 B1.03 B879.9 M642.9 M3.63 BCosto de los ingresos———————Otros costes de producción———————Amortización y depreciación (flujo de caja)126.4 M126.9 M135.1 M136.7 M145 M123.2 M540 M
Regeneron Pharmaceuticals, Inc. - Common Stock
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.